Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease in adverse reactions after repeated ivermectin treatment in onchocerciasis.

A Van der Lelij1, A Rothova, N Klaassen-Broekema

  • 1Department of Ophthalmology, Free University Amsterdam, The Netherlands.

Documenta Ophthalmologica. Advances in Ophthalmology
|October 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of conjunctival, episcleral and scleral thickness in healthy individuals using anterior segment optical coherence tomography.

Acta ophthalmologica·2023
Same author

Subconjunctival Rituximab Administration for the Treatment of Scleritis.

Ocular immunology and inflammation·2022
Same author

Clinical Relevance of Autoantibodies and Inflammatory Parameters in Non-infectious Scleritis.

Ocular immunology and inflammation·2021
Same author

Recurrences of Scleritis after Ocular Surgery.

Ocular immunology and inflammation·2021
Same author

Current insights in the pathogenesis of scleritis.

Experimental eye research·2020
Same author

Successful Tocilizumab Treatment for Scleritis.

Ocular immunology and inflammation·2019

Ivermectin treatment for onchocerciasis showed fewer side-effects with repeated doses. Initial ivermectin treatment requires medical supervision due to severe adverse reactions.

Area of Science:

  • Medical Parasitology
  • Tropical Medicine
  • Public Health

Background:

  • Onchocerciasis remains a significant public health concern in hyperendemic regions.
  • Ivermectin is a key drug for onchocerciasis treatment, but its side-effect profile requires careful monitoring.
  • Understanding the safety and efficacy of repeated ivermectin dosing is crucial for treatment strategies.

Purpose of the Study:

  • To assess side-effects following multiple single-dose ivermectin treatments in onchocerciasis patients.
  • To determine if medical surveillance is consistently necessary for all ivermectin treatments.
  • To evaluate the impact of repeated ivermectin doses on treatment efficacy.

Main Methods:

  • Prospective study involving 87 onchocerciasis patients in Sierra Leone.

Related Experiment Videos

  • Patients received up to three single doses of ivermectin (150 micrograms/kg).
  • Adverse reactions were monitored after each dose; skin-snip tests assessed parasite load.

    • Main Results:

    • Side-effects significantly diminished with second and third ivermectin doses compared to the first (p < 0.005).
    • Severe side-effects occurred only after the initial dose, within 48 hours.
    • Despite two treatments, over 40% of patients still had positive skin-snip tests.

    Conclusions:

    • The first ivermectin treatment necessitates strict medical supervision for at least two days due to potential severe adverse reactions.
    • Repeated ivermectin dosing demonstrates improved tolerability and reduced side-effect incidence.
    • In hyperendemic areas, at least two ivermectin doses in the first year may be required for effective onchocerciasis control.